Nephrons and non-relapse mortality: simplified comorbidity index and acute kidney injury are associated with NRM in adults undergoing allogeneic hematopoietic cell transplant.

Autor:	Robinson CR; Division of Hematology and Oncology, University of Texas Southwestern Medical Center, Dallas, TX, United States., Habib A; Department of Hematology, The Ohio State University, Columbus, OH, United States., Klomjit N; Division of Nephrology and Hypertension, University of Minnesota, Minneapolis, MN, United States., Cao Q; Biostatistics and Bioinformatics, Masonic Cancer Center, University of Minnesota, Minneapolis, MN, United States., Holtan SG; Division of Hematology, Oncology, and Transplantation, University of Minnesota, Minneapolis, MN, United States.
Jazyk:	angličtina
Zdroj:	Frontiers in transplantation [Front Transplant] 2024 Mar 18; Vol. 3, pp. 1352413. Date of Electronic Publication: 2024 Mar 18 (Print Publication: 2024).
DOI:	10.3389/frtra.2024.1352413
Abstrakt:	The Simplified Comorbidity Index (SCI) is a recently published 5-component, pre-transplant tool to predict non-relapse mortality (NRM) in allogeneic hematopoietic cell transplantation (alloHCT) patients. The SCI captures chronic kidney disease (CKD) using estimated glomerular filtration rate (eGFR) based on the CKD-EPI equation (KDIGO 2021 CKD-EPI), which may be more sensitive to predict risk of NRM than the creatinine cut-off in the 16-component, Hematopoietic Cell Transplant-Comorbidity Index (HCT-CI). We retrospectively assessed the ability of the SCI to risk-stratify patients and the impact of acute kidney injury (AKI) to NRM in adults who underwent alloHCT at the University of Minnesota. We included 373 patients who underwent their first alloHCT between 2015 and 2019. Through multivariate analysis, we found that patients with an SCI of greater than 4 had a higher risk of NRM. Additionally, we noted that AKIs stages 2-3 prior to day +100 was independently associated with a 3-fold greater NRM than patients who did not experience clinically significant AKI. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (© 2024 Robinson, Habib, Klomjit, Cao and Holtan.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu